milademetan,venetoclax
rain therapeutics,Abbvie,roche
['milademetan', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
3/6 a phase i/ii study of milademetan (mdm2i) in combination with ldac +/- ven in aml
r/r aml + wt tp53; n=16
orr= 2/16 (13%); blast redu. 5/16 (31%)
tp53 mut post rx=1/16 (6%)
@ dinardo 
Leukemia fellow at MD Anderson.
(CMC Vellore and AIIMS New Delhi alumnus).Opinionated and adore rationality!Tweets are my own. Science for humanity? 
??????????